1780.TWO Allied Biotech Corporation
- Market cap
- TWD 2.59B
- P/E
- 12.8x
- P/B
- 1.73x
- ROE
- 8.9%
- Dividend yield
- 3.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1780.TWO undervalued?
Graham number1780.TWO trades 0.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allied Biotech Corporation fundamental analysis
No fundamental analysis for Allied Biotech Corporation yet.
Allied Biotech Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allied Biotech Corporation
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. It also provides Canthaxanthin, wh…
Full company profileAllied Biotech Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allied Biotech Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 574M | 682M | 765M | 639M | 618M | 677M | 717M | 720M | 807M | 850M | 997M |
| Gross Profit | 219M | 232M | 301M | - | 241M | 258M | 271M | 246M | 258M | 309M | 400M |
| Operating Income | 63.7M | 89.9M | 145M | 137M | 103M | 28.8M | 102M | 88.7M | 88.1M | 120M | 171M |
| EBITDA | 104M | 143M | 223M | 199M | 173M | 94.1M | 271M | 205M | 206M | 242M | 244M |
| Net Income | 40.2M | 71.0M | 133M | 107M | 79.5M | 13.0M | 147M | 97.4M | 101M | 129M | 135M |
| EPS | 0.43 | 0.75 | 1.41 | 1.12 | 0.83 | 0.14 | 1.53 | 1.01 | 1.05 | 1.35 | 1.24 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | - | 1.95B | 2.26B | 2.44B | 2.18B | 2.08B | 2.26B | 2.09B | 2.56B |
| Total Liabilities | - | - | - | 791M | 1.12B | 1.36B | 999M | 910M | 1.06B | 857M | 1.04B |
| Shareholders' Equity | - | - | - | 1.16B | 1.15B | 1.08B | 1.18B | 1.17B | 1.20B | 1.23B | 1.52B |
| Cash & Short-term Investments | - | - | - | 760M | 966M | 1.14B | 793M | 725M | 987M | 789M | 1.16B |
| Total Debt | - | - | - | 688M | 1.00B | 1.25B | 838M | 797M | 955M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | - | 59.5M | 72.4M | 164M | 138M | 224M | 217M | 234M |
| Capital Expenditure | - | - | - | 0.00 | 56.8M | 50.0M | 54.7M | 47.9M | 26.8M | 33.6M | 39.8M |
| Free Cash Flow | - | - | - | - | 2.66M | 22.4M | 110M | 89.7M | 197M | 184M | 194M |
| Ratios | |||||||||||
| ROE | - | - | - | 9.2% | 6.9% | 1.2% | 12.4% | 8.3% | 8.4% | 10.5% | 8.9% |
| ROA | - | - | - | 5.5% | 3.5% | 0.5% | 6.7% | 4.7% | 4.5% | 6.2% | 5.3% |
| Net Profit Margin | 7.0% | 10.4% | 17.4% | 16.7% | 12.9% | 1.9% | 20.5% | 13.5% | 12.5% | 15.2% | 13.5% |
| Debt to Equity | - | - | - | 0.59x | 0.88x | 1.15x | 0.71x | 0.68x | 0.80x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allied Biotech Corporation dividends
- Dividend yield
- 3.71%
- Forward dividend
- 1.25 TWD
- Payout ratio
- 74.2%
- Ex-dividend date
- Jun 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 96.0M | 1.00 | 74.2% |
| 2024 | TWD 81.4M | 0.85 | 80.7% |
| 2023 | TWD 114M | 1.19 | 117.5% |
| 2022 | TWD 47.7M | 0.50 | 32.5% |
| 2021 | TWD 76.1M | 0.80 | 583.7% |
| 2020 | 94.9M | 0.99 | 119.4% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Allied Biotech Corporation
- Insiders 35.39%
- Institutions 13.52%
- Public & others 51.10%
- Shares outstanding 109M
- Free float 67.0M
Allied Biotech Corporation company profile
- Company name
- Allied Biotech Corporation
- Ticker
- 1780.TWO
- ISIN
- TW0001780005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- No. 71, Tun Hua South Road, Taipei, Taiwan, 106045
- Phone
- 886 2 2703 0209
- Website
- altratene.com
About Allied Biotech Corporation
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. It also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. The company was founded in 2001 and is headquartered in Taipei, Taiwan.
Allied Biotech Corporation management
3- Mr. Qing Hui LinCEO & Director
- Mr. Bin YangChief Operating Officer
- Xinghui YangAccounting Supervisor